Preimplantation Genetics Diagnosis Market Size & Share, by Application (Single Gene Disorders, Chromosomal Abnormalities, HLA Typing, Gender Selection); Technology; Test Type; End user; Product - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2026-2035

Preimplantation Genetics Diagnosis Market - Regional Analysis

North America Market Insights

North America is estimated to capture the highest share of 42.2% in the preimplantation genetics diagnosis market during the analyzed tenure. The advanced healthcare infrastructure, high ART adoption rates, and a strong presence of genetic testing pioneers are the foundational pillars of the region's dominance in this sector. The landscape also benefits from greater awareness about genetic disorders, increasing maternal age, and favorable reimbursement policies in selected regions. These factors are collectively fueling the widespread use of PGD in North America, which is stimulated further by NGS innovations and robust investment in fertility research.

The U.S. leads the regional market with a majority share in revenue generation. The country's augmentation in this sector is backed by a well-established network of fertility clinics and a strong emphasis on advanced reproductive technologies. This cohort of innovation can be exemplified by the commencement of Ovation Fertility's progress toward enhancing and expanding the genetic testing options, in collaboration with Genomic Prediction in October 2022. Such commercial success, coupled with the rising awareness of hereditary conditions, increased demand for PGD as part of IVF procedures across the nation.

Canada is establishing propagating as an emerging landscape of the regional preimplantation genetics diagnosis market. The increasing acceptance of ART and rising awareness of genetic health are cumulatively fueling the country's significance in this sector. The demand for PGD in Canada is also pledged to delayed family planning and a heightened focus on preventing hereditary disorders. Besides, government efforts to enhance the reproductive capacity of the country through reinforcement in public healthcare infrastructure and investment in medical research are also backing the gradual expansion of PGD services in Canada.

APAC Market Insights

Asia Pacific is poised to augment the global market as the fastest-growing region by the end of 2035. The massive population, increasing reproduction-related health issues, and growing awareness of genetic disorders are creating a surge in PGD services across the region. The remarkable improvement in healthcare systems, policies, and access is also benefiting the sector. Besides, the rapidly expanding medical tourism and a growing middle-class population are contributing to a greater cash inflow in this category. Moreover, as cultural attitudes shift and healthcare infrastructure continues to develop, APAC is expected to play an increasingly significant role in the global PGD market.

China is a hub of both the global producers of raw materials and a massive consumer base in the preimplantation genetics diagnosis market. The nation's amplifying citizen count, increasing infertility rates, and growing emphasis on the MedTech industry are contributing to its regional proprietorship. The rising average maternal age, coupled with a greater focus on preventing genetic disorders, has also increased interest in PGD among prospective parents. Further, as public awareness and regulatory clarity enhances, China is positioned to become a major contributor to the region's largest asset for PGD market expansion.

India is an influential landscape, filled with opportunities for the Asia Pacific market. It is primarily backed by the substantially expanding IVF industry and government initiatives to promote healthy pregnancy. The country's expanding healthcare and diagnostic infrastructure, coupled with the availability of cost-effective fertility treatments, has made ART-related assessments more accessible. Public efforts in support of this cohort can further be exemplified by the collaboration between AIIMS Jammu and 4baseCare in January 2025 to launch the Centre for Advanced Genomics and Precision Medicine in India.

Country-wise IVF & ART Adoption Trends

Source: VARTA and NLM

Europe Market Insights

Europe is estimated to hold a steady position in the global preimplantation genetics diagnosis market between 2026 and 2035. The well-established medical systems, increasing infertility rates, and strong awareness of genetic disorders are the major growth drivers in this landscape. The region also benefits from advanced clinical innovations, widespread availability of ART, and standardized regulatory frameworks that ensure the safe and ethical use of PGD. Besides, continuous tech-based integration in healthcare and increasing government allocations to extensive fertility research are expected to expand the territory of Europe in this field.

Germany is a key landscape of the Europe market, which is highly attributable to high standards of medical care and the presence of global MedTech pioneers. Increasing occurrence and severity of genetic disorders, along with the rising average maternal age, also contribute to the rise in demand for PGD. Moreover, the country’s well-regulated IVF industry ensures the ethical use of reproductive technologies, where ongoing R&D and innovations in genetic testing technology secure large-scale utilization in this sector.

The UK is a prominent growth engine of the regional market, which is achieved through its advanced healthcare system and progressive regulatory framework for ARTs. Further, testifying to the high utilization and large consumer base, the Human Fertilisation and Embryology Authority (HFEA) unveiled that more than 77,500 IVF cycles were performed for approximately 52,400 patients in the UK in 2023 alone. This caused over 20,700 childbirths, which constitutes 3.1% of all births in the country during the same timeline. Such an evolving dynamics of the IVF industry underscores the country's potential to avail new opportunities for this sector.